Delving into the Latest Updates on Glyburide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide

+ [22]

Target

Kir6.2 x SUR1

Mechanism

Kir6.2 agonists(potassium inwardly rectifying channel subfamily J member 11 agonists), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseOther Diseases

Active Indication

Inactive Indication

Brain ConcussionBrain ContusionBrain Edema+ [6]

Originator Organization

Pfizer Inc.

Active Organization

Ammtek Ltd.

Tianjin Lisheng Pharmaceutical Co., Ltd.

Pfizer Inc.

+ [1]

Inactive Organization

Remedy Pharmaceuticals, Inc.

Biogen, Inc.

Jiangsu Aosaikang Pharmaceutical Co. Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1981),

Diabetes Mellitus

RegulationOrphan Drug (EU), Priority Review (CN)

Login to view timeline

Structure

Molecular FormulaC23H28ClN3O5S

InChIKeyZNNLBTZKUZBEKO-UHFFFAOYSA-N

CAS Registry10238-21-8

This study aims to compare the maternal, fetal, and neonatal outcomes associated with the use of metformin versus glyburide for managing gestational diabetes.
The objective is to assess the safety and effectiveness profiles of both medications as potential alternatives to initiating insulin therapy.

Start Date01 Jan 2025

Sponsor / Collaborator

Assiut University

CTRI/2023/12/060716 / RecruitingNot ApplicableIIT

Role of Sulphonylurea-receptor1(SUR1) inhibition in Traumatic Brain injury (TBI): A randomized controlled trial to assess efficacy and safety of Glibenclamide in moderate to severe TBI - STRATEGY

Start Date01 Jan 2024

Sponsor / Collaborator

Indian Council of Medical Research

NCT05687500 / RecruitingPhase 2IIT

Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Start Date20 May 2023

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

100 Clinical Results associated with Glyburide

Login to view more data

100 Translational Medicine associated with Glyburide

Login to view more data

100 Patents (Medical) associated with Glyburide

Login to view more data

10,716

Literatures (Medical) associated with Glyburide

01 Jan 2025·Journal of Ethnopharmacology

Assessing the potential fasting and postprandial mechanisms involved in the acute hypoglycemic and anti-hyperglycemic effects of four selected plants from Iran used in traditional Persian medicine

Article

Author: Safavi, Fereshteh ; Espinoza-Hernández, Fernanda A ; Andrade-Cetto, Adolfo ; Escandón-Rivera, Sonia M

ETHNOPHARMACOLOGICAL RELEVANCEIn traditional Persian medicine (TPM), people often use herbal infusions as a dosage form to treat diseases related to hyperglycemia, known as 'dam-kardeh'. Traditionally, herbal preparations of Eryngium bungei Boiss. (E. b), Tragopogon buphthalmoides (DC.) Boiss. (T. b), Salvia hydrangea DC. ex Benth. (S. h), and Juniperus polycarpos K. Koch. (J. p) are used to manage diabetes in Iran. However, there is no evidence of their effectiveness in controlling glucose levels and their mechanisms remain unclear.AIM OF THE STUDYThis study aimed to investigate whether traditional doses of plant infusions can have hypoglycemic and/or anti-hyperglycemic effects during fasting and/or postprandial states and establish the basis for future research on their potential mechanisms of action.MATERIALS AND METHODSThe effects of traditional doses of herbal extracts on blood glucose levels in STZ-NA-induced hyperglycemic rats were investigated in 2-h acute tests during fasting and postprandial states (with a glucose load). In addition, the potential inhibitory effect in vitro of enzymes involved in relevant pathways, such as gluconeogenesis (fructose-1,6-bisphosphatase, FBPase and glucose-6-phosphatase, G6Pase), carbohydrate breakdown (intestinal α-glucosidases), and insulin sensitivity (protein tyrosine phosphatase 1B, PTP-1B) was evaluated. Acute toxicity tests were carried out and HPLC-SQ-TOF was used to analyze the chemical profiles of the plant extracts.RESULTSIn the fasting state, T. b, S. h, and E. b were as effective as glibenclamide in lowering blood glucose levels in hyperglycemic rats. Moreover, all three suppressed G6Pase and FBPase enzymatic activity by 90-97% and 80-91%, respectively. On the other hand, significant postprandial hypoglycemic efficacy was observed for E. b, S. h, and T. b. Based on the AUC values, T. b caused a reduction comparable to the therapeutic efficacy of repaglinide. When investigating the possible mechanisms of action involved in this activity, E. b, S. h, and T. b showed significant inhibition of PTP-1B in vitro (>70%). Finally, all plant extracts showed no signs of acute toxicity. Several compounds that may contribute to biological activities were identified, including phenolic acids and flavonoid glycosides.CONCLUSIONSThe present study supports the traditional use of T. b, E. b and S. h for the control of diabetes in the fasting and postprandial state. Moreover, these plants were found to be rich in bioactive compounds with hypoglycemic and antihyperglycemic activities. On the other hand, J. p, showed a modest effect only in the fasting state and after 90 min. Further studies are needed to expand these results by analyzing the chemical composition and using complementary experimental models.

01 Jan 2025·Journal of Ethnopharmacology

Bioactive phytocompounds profiling and the evaluation of analgesic, anti-inflammatory, and antihyperglycemic potential of Argyreia capitiformis (Poir.) Ooststr.: A combined n vitro, n vivo, and computational investigations

Article

Author: Islam, Md Naharul ; Biswas, Biswajit ; Islam, Md. Naharul ; Oisay, Debasree Sen ; Hasan, Md. Nazmul ; Hasan, Md Nazmul ; Biswas, Partha ; Medha, Maisha Maliha ; Devnath, Hiron Saraj ; Hossain, Arafat ; Sadhu, Samir Kumar ; Ahmed, Khondoker Shahin ; Hossain, Hemayet

ETHNOPHARMACOLOGICAL RELEVANCEArgyreia capitiformis (Poir.) Ooststr. (Convolvulaceae) is traditionally used by the Chakma community in the hilly region of Bangladesh to treat minor disorders such as pain.AIM OF THE STUDYThis study intended to determine the secondary metabolites to identify bioactive compounds and evaluate antioxidant potential, in vitro anti-inflammatory and in vivo analgesic, anti-inflammatory, and antihyperglycemic activities of A. capitiformis along with in silico investigations.MATERIALS AND METHODSChemical profiling was carried out using HPLC and GC-MS analysis. The analgesic effect was measured employing tail immersion and acetic acid-induced writhing methods. Following protein denaturation and formalin-induced paw edema, anti-inflammatory activity was studied. The antihyperglycemic potential was assessed using an oral glucose tolerance test (OGTT), while further mechanistic investigation was conducted using an alpha-glucosidase enzyme inhibitory assay. Simulations and molecular docking analyses were performed to ascertain the stability and binding affinities of the drug-protein complex.RESULTSA. capitiformis ethanolic extract confirmed the presence of phenolics, alkaloids, flavonoids, terpenoids, tannins, gums, steroids, and reducing sugars. HPLC analysis revealed the presence of eight polyphenolic compounds, the most abundant of which was myricetin (64.10 ± 0.14 mg per 100 g dry extract). Moreover, the GC-MS analysis revealed twenty-four molecules, the most important of which was 2,4-bis (dimethylbenzyl)-6-t-butylphenol (9.19%). The concentrations of total flavonoids, total terpenoids, total phenolics, and total tannins were ascertained to be 142.48 mg QE/g, 173.1 mg UAE/g, 19.35 mg GAE/g, and 13.05 mg GAE/g, respectively. Furthermore, the plant extract had a total antioxidant capacity of 388 mg AAE/g. In the writhing assay, the plant extract suppressed writhing by 59.73% and 76.99% at the doses of 250 and 500 mg/kg, respectively, compared to the standard diclofenac Na 87.17%, and in the tail immersion assay, the plant extract displayed a maximum average reaction time of 1.94 and 2.40 s at the doses of 250 and 500 mg/kg, respectively as compared to the control tramadol 2.84 s at 60 min. In an in vitro anti-inflammatory assay, the plant extract possessed an IC₅₀ of 95.51 μg/ml while diclofenac Na (standard drug) was found to be 69.50 μg/ml. Afterward, in vivo anti-inflammatory activity was observed in mice over a period, particularly after 3 h, the plant extract exerted maximum percent inflammation inhibitions of 36.36% and 45.45% at the doses of 250 and 500 mg/kg, respectively whereas ibuprofen the standard drug (100 mg/kg) exhibited 61.82%. The plant extract demonstrated antihyperglycemic activity, lowering blood sugar levels to 5.7 and 4.62 mM at doses of 250 and 500 mg/kg, respectively, as opposed to 8.58 mM in the control group. Meanwhile, the standard drug glibenclamide (5 mg/kg) dropped blood glucose levels to 2.38 mM in 60 min after glucose administration. Molecular docking (MD) and molecular dynamics simulation (MDS) studies support the stability of the protein complex responsible for exerting pharmacological activities.CONCLUSIONA. capitiformis extract exhibited strong medicinal values supporting its traditional uses.

01 Dec 2024·Fundamental & Clinical Pharmacology

Involvement of different K⁺ channel subtypes in hydrogen sulfide‐induced vasorelaxation of human internal mammary artery

Article

Author: Nenezic, Dragoslav ; He, Guo‐Wei ; Milojevic, Predrag ; Kanjuh, Vladimir ; Yang, Qin ; Stojanovic, Ivan ; Novakovic, Aleksandra ; Marinko, Marija

AbstractBackgroundChanges in K+ channel expression/function are associated with disruption of vascular reactivity in several pathological conditions, including hypertension, diabetes, and atherosclerosis. Gasotransmitters achieve part of their effects in the organism by regulating ion channels, especially K+ channels. Their involvement in hydrogen sulfide (H2S)‐mediated vasorelaxation is still unclear, and data about human vessels are limited.ObjectiveTo determine the role of K+ channel subtypes in the vasorelaxant mechanism of H2S donor, sodium‐hydrosulfide (NaHS), on isolated human internal mammary artery (HIMA).ResultsNaHS (1 × 10−6–3 × 10−3 mol/L) induced a concentration‐dependent relaxation of HIMA pre‐contracted by phenylephrine and high K+. Among K+ channel blockers, iberiotoxin, glibenclamide, 4‐aminopyridine (4‐AP), and margatoxin significantly inhibited NaHS‐induced relaxation of phenylephrine‐contracted HIMA (P < 0.01), whereas in the presence of apamin/1‐[(2‐chlorophenyl) diphenylmethyl]‐1H‐pyrazole (TRAM‐34) combination, the HIMA relaxation was partially reduced (P < 0.05). The effect of NaHS was antagonized by NO pathway inhibitors, L‐NAME and KT5823, and by cyclo‐oxygenase inhibitor, indomethacin (P < 0.01). Under conditions of blocked NO/prostacyclin synthesis and release, apamin/TRAM‐34 and glibenclamide caused further decrease in NaHS‐induced vasorelaxation (P < 0.01), while iberiotoxin, 4‐AP, and margatoxin were without additional effect (P > 0.05). In the presence of nifedipine, NaHS induced partial relaxation of HIMA (P < 0.01).ConclusionOur results demonstrated that H2S donor, NaHS, induced concentration‐dependent relaxation of isolated HIMA. Vasorelaxant mechanisms of H2S included direct or indirect opening of different K+ channel subtypes, KATP, BKCa, SKCa/IKCa, and KV (subtype KV1.3), in addition to NO pathway activation and interference with extracellular Ca2+ influx.

26

News (Medical) associated with Glyburide

19 Nov 2024

·www.prnewswire.com

Remedy Pharmaceuticals Receives FDA Guidance to Advance CIRARA for Treatment of Severe Stroke

NEW YORK, Nov. 19, 2024 /PRNewswire/ -- Remedy Pharmaceuticals, a leader in stroke drug development, announced today that a Type C meeting held with the U.S. Food and Drug Administration (FDA) on October 16, 2024, provided valuable feedback on the design of a Phase 3 trial of its investigational drug, CIRARA, for large hemispheric infarction (LHI), a severe and life-threatening form of ischemic stroke. A Type C meeting is a formal discussion between the FDA and a sponsor to review product development plans. Remedy sought feedback on the proposed Phase 3 study, and the meeting, along with meeting minutes, clarified key aspects of the trial's design. "The FDA's feedback reinforces our confidence in our planned Phase 3 trial design and CIRARA's potential to address the urgent unmet needs of patients with LHI," said Sven Jacobson, CEO of Remedy Pharmaceuticals. "We are committed to advancing CIRARA and to redefining the standard of care for this devastating condition characterized by high mortality and severe long-term disability." About Large Hemispheric Infarctions Large hemispheric infarctions (LHIs) are severe strokes affecting a significant portion of one cerebral hemisphere, typically involving the territory supplied by the middle cerebral artery (MCA). These strokes result in extensive brain damage and often lead to life-threatening complications such as severe cerebral edema, increased intracranial pressure, and brain herniation. About Remedy Pharmaceuticals: New York-based Remedy Pharmaceuticals, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing and bringing lifesaving treatments to people affected by acute central nervous system (CNS) diseases and injuries. Contact: Sven Jacobson CEO Remedy Pharmaceuticals 212.586.2226 [email protected] SOURCE Remedy Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3

22 Oct 2024

·www.prnewswire.com

Remedy Pharmaceuticals Announces FDA Orphan Drug Designation Granted for the Treatment of Large Territory Acute Ischemic Stroke with CIRARA

NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of "large territory acute ischemic stroke," which includes large hemispheric infarctions (LHI). LHI is a particularly severe form of ischemic stroke caused by a blockage in the one of two large blood vessels in the brain: internal carotid artery or middle cerebral artery (MCA), which cuts off the blood supply to large areas of the brain, resulting in severe swelling, significant mortality, and high disability rates. "The Orphan Drug Designation for CIRARA underscores the uniqueness of large territory ischemic strokes in terms of mechanism and universally poor outcomes in contrast to smaller strokes," said Sven Jacobson, CEO of Remedy Pharmaceuticals. "This designation will accelerate our efforts to bring CIRARA to acute ischemic stroke patients at the highest risk of severe disability and death." The FDA's Orphan Drug Designation program provides orphan status to drugs or biologics intended to treat diseases or conditions that affect fewer than 200,000 people in the United States. Sponsors of medicines with Orphan Drug Designation may be eligible for various incentives, including tax credits for qualified clinical trials, prescription drug user fee exemptions, and seven years of marketing exclusivity upon FDA approval. About Large Hemispheric Infarction A large hemispheric infarction is a particularly severe type of ischemic stroke that affects a substantial portion of the brain. This occurs when there is a blockage in a major cerebral artery, such as the middle cerebral artery (MCA) or the internal carotid artery (ICA), both of which are responsible for supplying large regions of the brain with oxygen-rich blood. Treatment for LHI typically involves rapid revascularization strategies to restore blood flow, such as mechanical thrombectomy or intravenous thrombolysis (administering clot-dissolving drugs like tPA). However, the large scale of the infarction and the resultant edema leads to poorer outcomes compared to smaller strokes, with many patients suffering long-term disability or, in some cases, death. About Remedy Pharmaceuticals: New York-based Remedy Pharmaceuticals, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing and bringing lifesaving treatments to people affected by acute central nervous system (CNS) diseases and injuries. Contact: Sven Jacobson CEO Remedy Pharmaceuticals 212.586.2226 [email protected] SOURCE Remedy Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Orphan Drug

22 Oct 2024

·www.biospace.com

Remedy Pharmaceuticals Announces FDA Orphan Drug Designation Granted for the Treatment of Large Territory Acute Ischemic Stroke with CIRARA

NEW YORK , Oct. 22, 2024 /PRNewswire/ -- Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of “large territory acute ischemic stroke,” which includes large hemispheric infarctions (LHI). LHI is a particularly severe form of ischemic stroke caused by a blockage in the one of two large blood vessels in the brain: internal carotid artery or middle cerebral artery (MCA), which cuts off the blood supply to large areas of the brain, resulting in severe swelling, significant mortality, and high disability rates. “The Orphan Drug Designation for CIRARA underscores the uniqueness of large territory ischemic strokes in terms of mechanism and universally poor outcomes in contrast to smaller strokes,” said Sven Jacobson , CEO of Remedy Pharmaceuticals. “This designation will accelerate our efforts to bring CIRARA to acute ischemic stroke patients at the highest risk of severe disability and death.” The FDA’s Orphan Drug Designation program provides orphan status to drugs or biologics intended to treat diseases or conditions that affect fewer than 200,000 people in the United States . Sponsors of medicines with Orphan Drug Designation may be eligible for various incentives, including tax credits for qualified clinical trials, prescription drug user fee exemptions, and seven years of marketing exclusivity upon FDA approval. About Large Hemispheric Infarction A large hemispheric infarction is a particularly severe type of ischemic stroke that affects a substantial portion of the brain. This occurs when there is a blockage in a major cerebral artery, such as the middle cerebral artery (MCA) or the internal carotid artery (ICA), both of which are responsible for supplying large regions of the brain with oxygen-rich blood. Treatment for LHI typically involves rapid revascularization strategies to restore blood flow, such as mechanical thrombectomy or intravenous thrombolysis (administering clot-dissolving drugs like tPA). However, the large scale of the infarction and the resultant edema leads to poorer outcomes compared to smaller strokes, with many patients suffering long-term disability or, in some cases, death. About Remedy Pharmaceuticals: New York -based Remedy Pharmaceuticals, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing and bringing lifesaving treatments to people affected by acute central nervous system (CNS) diseases and injuries. Contact: Sven Jacobson CEO Remedy Pharmaceuticals 212.586.2226 sven@remedypharmaceuticals.com View original content to download multimedia: SOURCE Remedy Pharmaceuticals

Orphan Drug

100 Deals associated with Glyburide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00336	Glyburide	A10BB01	DB01016

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
6q24-Related Transient Neonatal Diabetes Mellitus	IS	Ammtek Ltd.	24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus	LI	Ammtek Ltd.	24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus	NO	Ammtek Ltd.	24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus	EU	Ammtek Ltd.	24 May 2018
Neonatal diabetes mellitus	EU	Ammtek Ltd.	24 May 2018
Neonatal diabetes mellitus	IS	Ammtek Ltd.	24 May 2018
Neonatal diabetes mellitus	NO	Ammtek Ltd.	24 May 2018
Neonatal diabetes mellitus	LI	Ammtek Ltd.	24 May 2018
Diabetes Mellitus, Type 2	US	Pfizer Inc.	01 May 1984
Diabetes Mellitus, Type 2	US	Sanofi-Aventis U.S. LLC	01 May 1984
Diabetes Mellitus	CN	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infarction	Phase 1	AU	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	US	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	CN	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	BR	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	JP	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	CZ	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	CH	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	GB	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	ES	Remedy Pharmaceuticals, Inc.	29 Aug 2018
Infarction	Phase 1	BE	Remedy Pharmaceuticals, Inc.	29 Aug 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CHARM (PRNewswire) Manual	Phase 3	Stroke	535	CIRARA	(qsrroemdnj): OR = 2.22, P-Value = 0.03	Positive	01 Oct 2024
				placebo
NCT02864953 (CHARM, PRNewswire) Manual	Phase 3	Brain Infarction	535	CIRARA	(kmykdrgxuh): OR = 1.8, P-Value = 0.01 View more	Positive	03 Sep 2024
				Placebo
NCT05137678 (Pubmed \| Neurocrit Care)	Phase 4	Aneurysm, Intracranial Berry, 1 serum neuron-specific enolase (NSE) \| soluble protein 100B (S100B)	111	Glibenclamide tablet 3.75 mg/day	djwlkntblg(emxtgktyqs) = pgjgfpxxqf vwdgomitfz (zdarplykob )	Negative	08 Aug 2024
				Glibenclamide (Control group)	djwlkntblg(emxtgktyqs) = weogwjojfk vwdgomitfz (zdarplykob )
CHARM (PRNewswire) Manual	Phase 3	Brain Infarction	535	BIIB093	(btnztpprek) = statistically significant improvements in functional outcomes (Odds Ratio 1.66, p=0.03). fpqztikkvs (ufsvexubjc )	Positive	29 May 2024
				Placebo
NCT02864953 (CHARM, CTgov)	Phase 3	Brain Edema \| Brain Infarction \| Infarction	535	Placebo (Placebo)	iiyfuojehd(knwteqfowy) = jvsjywkqww fvddqgozwx (uhtuogfgzj, ftiycpakvd - hcaornklen) View more	-	09 Jan 2024
				BIIB093 (BIIB093)	iiyfuojehd(knwteqfowy) = qajytyndld fvddqgozwx (uhtuogfgzj, vtnvgwaegv - tjxfwgtjlk) View more
NCT00965991 (CTgov)	Not Applicable	Diabetes, Gestational	149	Metformin (Metformin)	zewvmesdda(elahulyooq) = vsqgnlivmv laiapnzcnk (jiinzhfdmg, sagacbsixj - ygcttvoaxc)	-	21 Dec 2023
				Glyburide (Glyburide)	zewvmesdda(elahulyooq) = bmpidbitpr laiapnzcnk (jiinzhfdmg, ijckuqydsq - cmshnsrmge)
NCT03954041 (ASTRAL, CTgov)	Phase 2	Brain Contusion	92	Placebo	nimghlsniw(plvlnzenhg) = ydixntptsn dqvqhaoodx (bmmnvxwkwt, alerqljazh - srijniegzb) View more	-	20 Dec 2023
ESPE2023	Not Applicable	Neonatal diabetes mellitus KCNJ11 gene mutation	-	Insulin therapy	(jryizyaywq) = gqfusxeflz havugocmjn (xhdqtmexct, N - 0.92 to 3.73)	-	21 Sep 2023
				Glibenclamide	(jryizyaywq) = bdpknmregq havugocmjn (xhdqtmexct )
NCT02460874 (CTgov)	Phase 1/2	Brain Edema \| Brain metastases	1	Glyburide (Pilot Portion)	fqyyhwtkla(zismadpsbs) = fpdkurjjpj ffobwycpcz (rbxayahxpo, fftwtovkbp - ifktokrnwq) View more	-	21 Sep 2022
				Placebo+Glyburide (Randomized Portion)	fqyyhwtkla(zismadpsbs) = zysovtntiw ffobwycpcz (rbxayahxpo, awchtnetdb - dzjxmturdu) View more
NCT02524379 (SCING, CTgov)	Phase 1/2	Traumatic spinal cord injury \| acute spinal cord injury	3	Glyburide	dwqiauwyaq(uhgbtlsgmj) = roaaohhzto cqtuoppmfx (cieyctguvp, cryqvmdpvj - gtivxmugdh) View more	-	07 Jun 2022